Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer.

Brian W LabadieDavid S MorrisAlan H BryceRobert GivenJingsong ZhangWassim AbidaSimon ChowdhuryAkash Patnaik

Published in: Cancer management and research (2022)

Rucaparib's recent approval for treatment of BRCA-mutant mCRPC is practice changing. Proper management of TEAEs will allow maximum treatment benefit for patients receiving rucaparib.

Keyphrases

healthcare
primary care
replacement therapy